Answers are grounded in this paper and cite their sources.
Purpose of Review Minimally invasive surgical therapies (MISTs) have emerged as an alternative to the standard surgical treatment for patients with BPH. The purpose of this review is to summarize the primary literature evaluating clinical efficacy, safety, and durability of these procedures. Recent Findings UroLift and Rezūm have been established to offer significant improvement in urinary symptoms, Qmax, while preserving ejaculatory function. Emerging techniques such as Optilume and implantable prostatic devices show promising short-term outcomes in improvement of urinary symptoms with preservation of sexual function, but longer-term durability remains to be established. There is a lack of high-quality studies comparing MISTs head-to-head or to surgical standards. Summary MISTs offer symptom improvement with preservation of sexual function in the ambulatory setting. Individual procedures offer distinct advantages and treatment selection should be individualized through shared decision-making incorporating both patient preferences and anatomic considerations.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: